← Back to Search

Other

Miebo treatment for Dry Eye Syndrome

Phase 4

Waitlist Available

Research Sponsored by Bausch & Lomb Incorporated

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up postop day 30 ± 7 days

Awards & highlights

Study Summary

This trial will look at how Miebo™ affects eye measurements before and after surgery.

Who is the study for?

This trial is for individuals with Dry Eye Syndrome who are preparing for eye surgery. The study aims to include those who need accurate measurements of their eyes (biometry/keratometry) before surgery and want to improve the precision of their vision after the operation.Check my eligibility

What is being tested?

The study is testing Miebo™, a treatment designed to help with Dry Eye Syndrome. It's an open-label Phase 4 trial, meaning everyone knows they're getting Miebo™, and it's being conducted across multiple centers.See study design

What are the potential side effects?

Since specific side effects aren't listed here, generally speaking, treatments for dry eye syndrome can sometimes cause mild burning or irritation in the eyes upon application.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ postop day 30 ± 7 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~postop day 30 ± 7 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and postop day 30 ± 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean difference between absolute deviations from predicted refractive error in the study eye.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Miebo treatmentExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Miebo

2023

Completed Phase 4

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor

251 Previous Clinical Trials

57,319 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the safety considerations associated with Miebo therapy in individuals?

"Given that this trial for Miebo treatment is in Phase 4 and the medication is already approved, our team at Power has rated its safety as a 3 on the scale."

Answered by AI

Is the current investigation open for participant enrollment?

"The ongoing trial, as documented on clinicaltrials.gov, is currently not in the recruitment phase. Its initial posting dates back to March 11th, 2024 and was last modified on April 2nd, 2024. Although this specific study is inactive regarding patient enrollment presently, there are a noteworthy total of 73 other trials actively seeking participants at this time."

Answered by AI

At how many different places is this clinical trial currently being conducted?

"Among the 5 active sites for this research project are Site 105 located in Laguna Hills, Site 102 situated in Petaluma, and Site 101 found in Somersworth."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

2024. "A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06346340.